Identification of Targetable<i>ERBB2</i>Aberrations in Head and Neck Squamous Cell Carcinoma

Abstract

ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.